TY - JOUR
T1 - Lower respiratory tract infection caused by respiratory syncytial virus
T2 - current management and new therapeutics
AU - Mazur, Natalie
AU - Martinon-Torres, Federico
AU - Baraldi, Eugenio
AU - Fauroux, Brigitte
AU - Greenough, Anne
AU - Heikkinen, Terho
AU - Manzoni, Paolo
AU - Mejias, Asuncion
AU - Nair, Harish
AU - Papadopoulos, Nikolaos G.
AU - Polack, Fernando P.
AU - Ramilo, Octavio
AU - Sharland, Mike
AU - Stein, Renato
AU - Madhi, Shabir A.
AU - Bont, Louis
PY - 2015/11
Y1 - 2015/11
N2 - Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade indude 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation.
AB - Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade indude 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation.
KW - FLOW NASAL CANNULA
KW - NEBULIZED HYPERTONIC SALINE
KW - RANDOMIZED CLINICAL-TRIAL
KW - EARLY-LIFE
KW - NEUTRALIZING ANTIBODY
KW - VIRAL BRONCHIOLITIS
KW - MONOCLONAL-ANTIBODY
KW - VACCINE CANDIDATE
KW - UNITED-STATES
KW - RISK-FACTORS
U2 - 10.1016/S2213-2600(15)00255-6
DO - 10.1016/S2213-2600(15)00255-6
M3 - Literature review
C2 - 26411809
SN - 2213-2600
VL - 3
SP - 888
EP - 900
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 11
ER -